welcome to the OptumRx Drug store insights podcast in this forum we'' ll discuss the most up to date and also most impactful occasions in Pharmacy Benefit Management with a concentrate on the emerging Solutions required to control expenses and also make sure quality of treatment I'' m your host Scott Draeger [Music] today I'' m signed up with by Mike einshofer Principal Drug store officer at OptumRx Mike can you show to us a little bit about your professional background and also exactly what a primary Pharmacy officer is in charge of oh certain many thanks Scott as well as many thanks for having me today so I'' ve remained in healthcare regarding 25 years uh so a pharmacist you recognize across a great deal of different aspects within the sector I started as a retail pharmacologist dealing with a large chain down in in Winston-Salem North Carolina after graduating from the College of Pittsburgh pharmacy school after a few years of doing that I decided I intended to go back to finish college so I went after an organization level I appeared and worked for a health system or in fact a local health center for a time period therefore my first actually six years of my career remained in direct Drug store practice in retail and also Medical facility settings uh I then started work within a Health insurance called UPMC Health insurance plan in Western Pennsylvania which was a fantastic experience over a number of years I spent there which is where I truly started to discover how wellness insurance policy benefits work I began to actually begin to comprehend Specialty Drug store and also began my occupation after concerning six years at UPMC at Walgreens Specialized Pharmacy which was one of the largest specialized drug stores in the country invested a number of years at Walgreens Specialized Drug store in a leadership duty a variety of years after that at a at an exclusive equity-backed mid-tier health and wellness treatment solutions business and afterwards regarding a year ago I signed up with Optimus the principal Drug store police officer so what does the primary Pharmacy policeman do uh well I'' m incredibly happy with the job that every one of our 15 000 Facility Pharmacists and also other clinicians across the Enterprise do it to promote Drug store both coverage and also care for our people we we cover about 60 million plus lives within the United States throughout several different industries consisting of business Medicare Medicaid as well as after that we have a large sector of our of our organization which is what we call Business these are mostly employers local municipalities unions all groups that you know involved us to assist them give a drug store benefit to their employees and also their beneficiaries my task is to aid every one of those components whether it'' s Medicare Medicaid yet especially the the business plan enrollers to comprehend the kinds of Pharmacy programs that are available as well as what would work best for their participants treatment Micah as you recall at your profession 25 plus years in the sector what do you view as the the biggest changes uh within the career considering that given that you initially began oh wow um you know it'' s very different currently when I when I started a great deal of the medicines were sort of mainstream Key Treatment condition medications right you if if you'' ve been around enough time you keep in mind the purple pill right you remember Lipitor the these were medications that treated you know esophageal reflux condition and also high cholesterol right and they were you recognize they have actually you understand direct marketed customers or commercials and they treated you understand diseases that influenced you understand a big swath of the populace those illness place'' t gone'away but what ' s happened is in in in the last you understand years approximately for all the you know for most of key carry diseases excuse me if possibly diabetic issues as a tiny exception which still has some brand name medicines a great deal of the drugs in this group have actually gone generic and become you know much far more budget-friendly than when they were branded however that'' s exactly how the system ' s designed to work appropriate pharmaceutical manufacturers have a window of time where they can be the sole manufacturer of the medicine in the USA and after that after that time multiple makers enter the market the license no much longer applies and you see you see the price generally go down precipitously over time as more producers enter the marketplace so the biggest thing I see different Scott is that you have a number of the medical care conditions like high cholesterol and esophageal reflux illness you see those drugs now extremely extremely budget-friendly for the majority of clients however you see specialized medications best drugs that deal with very uncommon conditions like cystic fibrosis those didn'' t exist 20 some years earlier and also currently they are the fastest growing sector of Pharmacy as well as this produces a number of of adjustments leading it'' s a tremendous Renovation to The Human Problem the these medications are treating problems since or else were you know had a remarkable amount of of Anguish or even extra fatal oftentimes uh Way Means Beyond a normal life-span now they end up being persistent conditions therefore that'' s an excellent Testimony to the science behind all these growths yet they also deal with little populations and are for that reason really expensive therefore the large adjustment here is just how do the advantages sort of develop to make sure that members who in patients that need these high cost treatments can manage them right due to the fact that the you recognize a great deal of these are biologic and a whole lot of them are fairly new to the marketplace which means you know you won'' t have that kind of competition that'' ll that ' ll come years later on therefore we require to make certain that the benefits are made in a means that plans can afford them you know within their benefits and members can afford them you know when they require accessibility to them beforehand you chat you likewise discussed you understand a treatment of persistent conditions as well as exactly how the marketplace has actually progressed with the induction of an increasing number of common medications are exist generics readily available for specialty drugs and does that assistance sort of blunt these high rates that consumers are seeing yep they'' re available absolutely is Scott therefore the major illness remains in in specialized you know it'' s it ' s oncology or cancer cells it ' s cystic fibrosis it'' s rheumatoid joint inflammation'it ' s several sclerosis and afterwards there ' s great deals of other extremely rare hereditary illness you recognize that have really truly tiny individual populations mostly the the ones I simply go through the ones which you understand the leading 4 cancer CF rheumatoid joint inflammation several sclerosis they all have generics in them and inflam in and also there'' s other inflammatory conditions besides rheumatoid like psoriasis and also psoriatic arthritis which all kind of get abided together in a basic group of inflammatory diseases they all have some version of generics um I'' d say the most significant growth coming up as well as the one that doesn ' t have generics is rheumatoid joint inflammation as well as that'' s since that group is largely biologic in nature which implies it'' s not a normal medicine that treats us a lot many of the medications in in the inflammatory room are injectable as well as they'' re really complex particles that are made by not off a you know off a conveyor belt yet they'' re made in these huge bioreactors right that in fact make use of a biological system to make the medicine and also so standard common type of both from Governing and for producing perspective that it'' s various and so in in the biologic room you have what'' s called biosimilars biosimilars in the USA began to emerge numerous years ago the majority of the medications nevertheless to date get on the clinical side so they'' re instilled products beginning in February of next year it'' ll be a huge event because the globe ' s largest medicine which is treats inflammatory problems like psoriasis as well as rheumatoid joint inflammation and Crohn'' s a medication called Humira will certainly start to encounter biosimilar competition as well as this is a truly vital advancement for the entire market due to the fact that it'' ll now present direct competitors for Humira and you called we recognize and as we'' ve seen across you recognize not simply in the biosumal area however simply in you know in basic competition you recognize increases as more competitors enter the marketplace costs have a tendency to decrease with time and we'' re extremely confident that as that biosimilar market for human wrestlers to create very early next year that we'' ll start to see some much needed expense competitors arising within the inflammatory room Mike you discussed rheumatoid joint inflammation and also especially Humira for our audiences can you offer some context what would certainly a normal pair today pay for a prescription of Humira well I wear'' t I don ' t intend to perhaps highlight any kind of one certain medicine however however as a whole specialized medications can vary anywhere from a couple of thousand bucks to upwards of a hundred thousand dollars or even more per prescription the typical specialty patients around you know you can both operate at around fifty thousand bucks a year yet once more there'' s some you recognize that can extend into the Many millions so Mike how do consumers manage these medicines that'' s a terrific question and you recognize this is among the most hotly sort of questioned topics that you see in the political circles today and also it'' s a really really actually crucial subject I wish to invest a long time on we actually need to concentrate on just how healthy and balanced is the insurance policy benefit styles within our the industry that we all take part in right not just the expense of the medicine a great deal of the study out there sustains you know over three billion bucks for a real novel new therapy to make it to the marketplace so the solution isn'' t just well the drugs need to be low-cost because after that you'' d have no advancement in the industry where we have to look is exactly how do we gain access to affordable programs for members and also clients that require these drugs you know if you have a ten thousand buck medicine right which is about the rate of a dental oncology a dental cancer medication if it'' s ten thousand dollars and also you cut the cost by eighty percent right it'' s still not affordable to most U.S people and also so once more back to the response we have to look Beyond just the medication price and also yes you recognize pbms get up daily to hold suppliers accountable for affordability of the medications they bring to the market that'' s one of the main jobs that we do as well as we do a truly great task at it however at the same time we have to find Solutions within the protection side and also protect individuals uh you recognize from what we call Economic poisoning so they can obtain the medications that they require make you you lay out a few of the obstacles from the client point of view what regarding the payer viewpoint the clients that you that you speak with day after day you recognize what type of approaches are offered to those entities and also as well as what do they require to assume concerning um or what ought to they think about when embracing these methods yeah that'' s an excellent question so very first is not also regarding specialty the the first point I I talk to a company around is what'' s their non-specialty insurance coverage resemble because what we locate Scott is most employers that we speak to are concerned regarding specialty because you recognize it'' s grown 8 times greater than the non-specialty side over the past 13 years the conventional side of of medication expenses has risen mostly in in line with rising cost of living particularly prices have actually increased significantly higher than that concerning Eightfold higher so of course as well as now it'' s about 50 of the of the company invest gets on specialized drugs but again as I said previously that 50 is originating from one to 2 percent of the population so employers are truly a little worried around what'' s the long-lasting view on being able to pay for the this kind of benefit uh as well as and the response is initial check out your non-specialty side due to the fact that we still see employers that will certainly cover certain medicines you recognize acne lotions that cost hundreds of dollars each right and that have the very same components in different formulations that are you understand very extremely very inexpensive like down in you know down in the 10 20 30 array so primary is allow'' s attend to all of what we consider to be the the waste within the benefit today and also that releases up some extra funds that is after that they'' re then offered for the a lot more expensive treatments after that when you check out specialty it'' s evaluating the long term and also you have to maintain 2 things in mind you understand one is we intend to make certain that every patient that has a medical need for among these medicines has access to it to do that and also keep it budget friendly for the employer we have to locate cost Solutions leading certainly is a medical necessity procedure right into onto itself acknowledging that not all Physicians practice versus the same finest techniques as well as as well as and you recognize within the medical literature and also FDA approvals to ensure that'' s where the previous off procedure enters place just to ensure that people that are recommended these high expense therapies wouldn'' t be much better matched with a various or perhaps no therapy in all in the case that occasionally we locate a a significant medication communication that makes the treatment that doctor desires to recommended just not clinically appropriate for the individual'' s specific private scenario the the third point is to consider things like exactly how do we discover other affordability Solutions uh that reduced the general expense via the advantage design you desire to have a capability to you'' ll hear the term refund sprayed best as well as basically all our discount is it stands for the pbm'' s ability to talk with a manufacturer and have the maker offer a discount for that certain drug when it'' s authorized for a patient this is what drives substantial affordability for our strategy sponsors because lacking that remedy manufacturers would have the ability to charge whatever they want in the market there'' d be extremely little control over the medical need demands to access a specific treatment and also expenses would rise substantially as a result of both of those points because again makers would not have kind of this checks as well as equilibriums procedure that pbms have in the marketplace that need them to not just show proof of just how their product is going to function yet additionally discuss with us on the cost in exchange for their setting within our formulary if 2 medications are offered in the industry and they both are medically doing the exact very same point we will discuss with each supplier to leading develop a connection with the one that we really feel is one of the most most budget-friendly choice for many patients always knowing Scott that there'' s an exemption procedure that exists when a person can ' t take advantage of the drug that benefits the most that'' s why we have a really durable exceptions process we take very seriously to see to it that those individual patients demands are accommodated additionally so Mike I I truly enjoyed our discussion thanks quite for investing time with us today oh thanks Scott international [Music] thanks for listening to the pharmacy insights podcast song in once again for more conversations on one of the most essential issues in Pharmacy care services [Music]
